National Ambulatory Medical Care Survey data were used to assess outpatient macrolide prescribing and selection. Conditions for which macrolides are firstline therapy represented 5% of macrolide prescribing. Family practitioners selected macrolides for children more frequently than pediatricians. Macrolides are an important antibiotic stewardship target.
Antibiotic use is the most important modifiable driver of antibiotic resistance, making judicious use of antibiotics critical to combatting antibiotic resistance. An estimated 30% of outpatient antibiotic prescribing in the United States is unnecessary [1] . Antibiotic prescribing for sinusitis, otitis media, and pharyngitis frequently results in nonrecommended antibiotic prescribing, with macrolides being the most common alternative antibiotic class prescribed [2] . Macrolides are infrequently recommended firstline therapies, suggesting that they are overprescribed. Previous research suggests variability in overall antibiotic prescribing rates among medical specialties [3] , but whether this variability extends to macrolide antibiotic prescribing is unclear. Our objectives were to identify the most frequent diagnoses associated with macrolide prescribing among children and adults and to examine patient-and clinician-level factors associated with inappropriate macrolide selection.
METHODS
The National Ambulatory Medical Care Survey (NAMCS) [4] from 2008-2011 was used to identify outpatient visits with macrolide prescriptions. In NAMCS, visits are sampled among nonfederal, office-based physicians using 3-stage probability sampling for geographic regions, physicians, and then clinical visits within a 1-week reporting period. Reporting periods are distributed randomly throughout the year, and weights are assigned to visits to produce national estimates of antibiotic prescribing. Estimates are adjusted for physician and item nonresponse. Our analyses use publicly available, de-identified data from subjects deemed nonhuman by the National Center for Emerging and Zoonotic Diseases human subjects advisor and as such did not require institutional review board review. Captured at each visit are patient demographic characteristics and visit characteristics, including up to 3 diagnoses and 8 medications prescribed, continued, or provided at the visit. Text diagnoses abstracted from medical records are translated to International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes by medical coders.
We classified diagnoses into 3 mutually exclusive categories based on clinical guideline recommendations. "Macrolides firstline" includes conditions for which macrolides are a firstline therapy (eg, community-acquired pneumonia); "macrolides not firstline" includes conditions for which antibiotics may be recommended but macrolides are not firstline therapy (eg, acute sinusitis); and "antibiotics unnecessary" includes conditions for which antibiotics are unnecessary or antibiotic indications are unclear (eg, acute bronchitis) (Appendix Table 1 ). For conditions for which clinical guidelines are lacking, The Johns Hopkins Antibiotic Guide [5] was used to determine macrolide appropriateness. For visits with multiple diagnoses, we assigned a single diagnosis by giving priority to diagnoses in the following order: "macrolide firstline, " "macrolide not-firstline, " and, last, "antibiotics unnecessary. " For example, a visit with both community-acquired pneumonia (macrolide firstline) and acute bronchitis (antibiotics unnecessary) listed as diagnoses would be classified as "macrolide firstline. " We excluded visits requiring parenteral antibiotics with no mention of oral antibiotics.
To identify patients and clinician characteristics associated with macrolide selection, multivariable logistic regression was used with the outcome variable of macrolide prescribing among visits with antibiotics prescribed (i.e., macrolide selection). Variables included in the model were diagnostic category, patient age group (pediatric or adult), sex (male or female), race (white or nonwhite), medical specialty of clinician (pediatrics, internal medicine, family/general practice, or other specialty), insurance status (private or nonprivate), US Census region (West, South, Northeast, and Midwest), and metropolitan statistical area (metropolitan or nonmetropolitan). STATA 12 (StataCorp, College Station, TX) was used to perform statistical analyses. Estimates with fewer than 30 observations, or those with a standard error of 30% or less, were not considered reliable and thus were not included. Visits were weighted to account for the multistage probability survey design. Alpha <0.05 was considered statistically significant.
RESULTS
In 2008-2011, 2399 visits led to macrolide prescriptions in NAMCS, and the mean national estimate of doctors' office visits resulting in macrolide prescriptions was 24.4 million annually (9.0 million pediatric visits and 15.4 million adult visits) (Appendix Table 2 ). Conditions for which macrolides are a firstline recommended therapy represented only 5% (7% of pediatric and 5% of adult macrolide prescriptions) of all visits in which macrolides were prescribed (Appendix Table 3 ). Conditions for which antibiotics are unnecessary represented 52% (40% of pediatric and 60% of adult prescriptions) of macrolide prescriptions. The most common diagnoses associated with macrolide prescriptions were sinusitis (18% of visits), bronchitis/bronchiolitis (14%), viral upper respiratory infection (URI; 11%), and pharyngitis (11%). Among pediatric visits, acute otitis media accounted for 16% of macrolide prescribing. After controlling for age, diagnostic tier, and other patient characteristics, family practitioners had higher odds of selecting macrolides for children compared with pediatricians (adjusted odds ratio [AOR], 1.42; 95% confidence interval [CI], 1.05-1.94) ( Table 1 ). No clinician specialty-level differences were identified for macrolide selection among adults. Other factors significantly associated with differences in macrolide selection included age group (pediatric visits), geographic region (both pediatric and adult visits), and insurance status (adult visits).
DISCUSSION
Only a small proportion (5%) of macrolide prescribing is for conditions for which macrolides are a firstline therapy. When examining risk factors associated with higher macrolide prescribing, visits by children to family practitioners were more likely to result in macrolide selection compared with pediatrician visits. Significant differences in macrolide prescribing were associated with insurance type, geographic region, and age group. Nonrecommended macrolide prescribing is concerning given the importance of minimizing both antibiotic resistance and direct patient harms incurred due to inappropriate antibiotic use.
Macrolides as a specific antibiotic class are a viable target for outpatient antibiotic stewardship efforts due to their widespread overuse. Azithromycin is the single most commonly prescribed outpatient antibiotic in the United States, accounting for 54.1 million prescriptions in 2011, or 174 prescriptions per 1000 persons [3] . Macrolides are the second most common antibiotic class prescribed in the United States [3] . However, the small proportion of macrolide prescriptions representing firstline recommended therapy in our study suggests that inappropriate macrolide prescribing is highly prevalent.
Inappropriate macrolide prescribing can be broadly categorized as either unnecessary antibiotic use or inappropriate macrolide selection. Unnecessary antibiotic use for bronchitis and viral URI represent easy targets for stewardship interventions as visits for these conditions should not result in an antibiotic. The high proportion of macrolide prescribing represented for conditions for which antibiotics may be indicated, but for which macrolides are not firstline, suggests that much opportunity for improvement remains regarding macrolide selection. Macrolides are frequently prescribed for sinusitis, acute otitis media, and pharyngitis. However, macrolides are a suboptimal choice for treating these infections due to increasing levels of Streptococcus pneumoniae and group A Streptococcus macrolide resistance [6] [7] [8] . Concern for decreasing effectiveness has led to national guidelines recommending against using macrolides for acute otitis media and sinusitis, regardless of penicillin allergy [6, 7] . However, macrolides are recommended for penicillin allergy in pharyngitis, and penicillin allergy evaluation may help address inappropriate macrolide selection [8] . Both unnecessary antibiotic use and inappropriate macrolide selection are inconsistent with known best practices for outpatient infections and put patients at risk for suboptimal outcomes and preventable adverse drug events. As increases in macrolide prescribing have been associated with increases in antibiotic resistance [9, 10] , it is imperative that antibiotic stewardship efforts reserve macrolides for infections that clearly benefit from macrolide treatment, such as community-acquired pneumonia, sexually transmitted infections, shigellosis, or pertussis.
For pediatric visits resulting in antibiotic prescriptions, family practitioners were more likely to select macrolides compared with pediatricians, when controlling for patient age, diagnosis, and other factors. Differences between family practitioners and pediatricians regarding management of pediatric patients have been observed [11] , but less is known regarding factors that may contribute to differences in antibiotic selection. This finding highlights meaningful differences in antibiotic selection for pediatric visits depending on clinician specialty. All clinicians providing care to children need to be engaged in outpatient stewardship, and outpatient pediatric stewardship initiatives need to extend beyond pediatricians. Stewardship efforts targeting family practitioners may be particularly important given their higher odds of macrolide selection for pediatric visits. Finally, for children, older patient age and private insurance were associated with higher levels of macrolide prescribing, and these may be considerations for targeted outpatient stewardship outreach.
Our study has limitations. We are unable to verify the accuracy of clinician-assigned diagnoses, and we are unable to stratify prescribing by provider type (eg, physician assistants and nurse practitioners). NAMCS collects a sample of office-based visits rather than patients; therefore, it is possible that multiple visits for the same illness episode may be captured. Finally, telephone or e-mail encounters are not captured. However, NAMCS is nationally representative and combines prescribing information with clinical data. Four years of data were needed to combine to increase sample size, and sampling changes in 2012 limited the comparability of more recent data to previous years. No information about drug allergy is included in NAMCS, so there was no information about drug allergy accounted for in our analyses.
Outpatient antibiotic stewardship in the United States has largely focused on improving antibiotic prescribing by targeting specific conditions for improvement. However, our study suggests that macrolides may warrant a novel Antibiotics unnecessary [1, 3, [16] [17] [18] [19] [20] All other conditions, including allergic rhinitis, asthma, acute bronchitis and bronchiolitis, influenza, nonsuppurative otitis media, and viral upper respiratory infection
